中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
22期
3455-3457,3458
,共4页
妊娠期高血压疾病%拉贝洛尔%硫酸镁
妊娠期高血壓疾病%拉貝洛爾%硫痠鎂
임신기고혈압질병%랍패락이%류산미
Pregnancy-induced hypertension disease%Labetalol%Magnesium sulfate
目的：观察拉贝洛尔联合硫酸镁治疗中重度妊娠期高血压疾病的临床疗效及安全性。方法78例中重度妊娠期高血压疾病患者按照随机数字表法分为对照组和观察组各39例，对照组单用硫酸镁治疗，观察组在应用硫酸镁基础上联合拉贝洛尔治疗，观察两组患者治疗前后平均收缩压和舒张压、24 h尿蛋白、孕产妇心率、胎心率和治疗后母婴结局情况。结果观察组治疗后收缩压（134．5±9．7） mmHg和舒张压（85．7±5．9）mmHg，较对照组的（145．2±10．8）mmHg、（96．1±6．8）mmHg显著下降（t＝4．60、7．21，均P＜0.05）；两组24 h尿蛋白、心率及胎心率等差异均无统计学意义（t＝0．52、0．56、0．15，均P＞0．05）；治疗后终止妊娠（7．7％）、胎盘早剥（0．0％）、胎儿窘迫（5．1％）、新生儿窒息发生率（7．7％）、产后出血（12．8％）、低体质量儿（12．8％）均显著低于对照组（33．3％、12．8％、20．5％、25．6％、33．3％、35．9％）（χ2＝7．86、5．34、4.13、4．52、4．62、5．64，均P＜0．05）；观察组治疗后总有效率94．9％，明显高于对照组的79．5％（χ2＝4．13，P＜0.05）；观察组不良反应的发生率15．4％，明显低于对照组的35．9％（χ2＝4．30，P＜0．05）。结论拉贝洛尔联合硫酸镁治疗中重度妊娠期高血压疾病效果满意，能有效降低平均血压，减少24 h尿蛋白含量，改善母婴结局，值得临床推广应用。
目的：觀察拉貝洛爾聯閤硫痠鎂治療中重度妊娠期高血壓疾病的臨床療效及安全性。方法78例中重度妊娠期高血壓疾病患者按照隨機數字錶法分為對照組和觀察組各39例，對照組單用硫痠鎂治療，觀察組在應用硫痠鎂基礎上聯閤拉貝洛爾治療，觀察兩組患者治療前後平均收縮壓和舒張壓、24 h尿蛋白、孕產婦心率、胎心率和治療後母嬰結跼情況。結果觀察組治療後收縮壓（134．5±9．7） mmHg和舒張壓（85．7±5．9）mmHg，較對照組的（145．2±10．8）mmHg、（96．1±6．8）mmHg顯著下降（t＝4．60、7．21，均P＜0.05）；兩組24 h尿蛋白、心率及胎心率等差異均無統計學意義（t＝0．52、0．56、0．15，均P＞0．05）；治療後終止妊娠（7．7％）、胎盤早剝（0．0％）、胎兒窘迫（5．1％）、新生兒窒息髮生率（7．7％）、產後齣血（12．8％）、低體質量兒（12．8％）均顯著低于對照組（33．3％、12．8％、20．5％、25．6％、33．3％、35．9％）（χ2＝7．86、5．34、4.13、4．52、4．62、5．64，均P＜0．05）；觀察組治療後總有效率94．9％，明顯高于對照組的79．5％（χ2＝4．13，P＜0.05）；觀察組不良反應的髮生率15．4％，明顯低于對照組的35．9％（χ2＝4．30，P＜0．05）。結論拉貝洛爾聯閤硫痠鎂治療中重度妊娠期高血壓疾病效果滿意，能有效降低平均血壓，減少24 h尿蛋白含量，改善母嬰結跼，值得臨床推廣應用。
목적：관찰랍패락이연합류산미치료중중도임신기고혈압질병적림상료효급안전성。방법78례중중도임신기고혈압질병환자안조수궤수자표법분위대조조화관찰조각39례，대조조단용류산미치료，관찰조재응용류산미기출상연합랍패락이치료，관찰량조환자치료전후평균수축압화서장압、24 h뇨단백、잉산부심솔、태심솔화치료후모영결국정황。결과관찰조치료후수축압（134．5±9．7） mmHg화서장압（85．7±5．9）mmHg，교대조조적（145．2±10．8）mmHg、（96．1±6．8）mmHg현저하강（t＝4．60、7．21，균P＜0.05）；량조24 h뇨단백、심솔급태심솔등차이균무통계학의의（t＝0．52、0．56、0．15，균P＞0．05）；치료후종지임신（7．7％）、태반조박（0．0％）、태인군박（5．1％）、신생인질식발생솔（7．7％）、산후출혈（12．8％）、저체질량인（12．8％）균현저저우대조조（33．3％、12．8％、20．5％、25．6％、33．3％、35．9％）（χ2＝7．86、5．34、4.13、4．52、4．62、5．64，균P＜0．05）；관찰조치료후총유효솔94．9％，명현고우대조조적79．5％（χ2＝4．13，P＜0.05）；관찰조불량반응적발생솔15．4％，명현저우대조조적35．9％（χ2＝4．30，P＜0．05）。결론랍패락이연합류산미치료중중도임신기고혈압질병효과만의，능유효강저평균혈압，감소24 h뇨단백함량，개선모영결국，치득림상추엄응용。
Objective To observe the clinical effect and safety of labetalol combined with magnesium sulfate in treating moderate and severe pregnancy-induced hypertension disease.Methods 78 cases with moderate and severe pregnancy-induced hypertension disease were divided into the control group and observation group according to random number table method,39 cases were in each group.The patients in the control group were given the magnesi-um sulfate only,and the patients in the observation group were given the treatment of labetalol combined with magnesi-um sulfate.After treatment,the average blood pressure,24h urine protein,maternal heart rate,fetus heart rate and pregnancy outcomes were detected.Results After treatment,the average blood pressure[(134.5 ±9.7) vs (85.7 ± 5.9)]mmHg of observation group was significantly lower than the control group(t=4.60,7.21,all P<0.05);the 24h urine protein,maternal heart rate and fetus heart rate had no significant difference (t=0.52,0.56,0.15,all P>0.05);the termination of pregnancy(7.7%),placental abruption(0.0%),fetal distress(5.1%),incidence of neo-natal asphyxia(7.7%),postpartum hemorrhage(12.8%),low birth weight(12.8%) were significantly lower than the control group(33.3%,12.8%,20.5%,25.6%,33.3%,35.9%) (χ2 =7.86,5.34,4.13,4.52,4.62,5.64,all P<0.05);the total effective rate of observation group with 37 cases (94.9%) was significantly higher than the con-trol group with 31 cases (79.5%) (χ2 =4.13,P<0.05);the incidence of adverse reactions of observation group with 15.4%was significantly lower than the control group with 35.9%(χ2 =4.30,P<0.05).Conclusion Labe-talol combined with magnesium sulfate in treating moderate and severe pregnancy-induced hypertension disease could effectively reduce the average blood pressure,the 24h urine protein and improve the pregnancy outcomes,which was worthy of clinical popularization and application.
